Cardiovascular disease

Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients

Retrieved on: 
Tuesday, February 27, 2024
Stroke, Caregiver, 2D, American Heart Association, USD, AI, IAT, Birth, 3D, Rotation, Neuro, PHG, Health, Patient, Diagnosis, Machine learning, LVO, Ultra, Workflow, AEX, Cardiovascular disease, Medical imaging

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Minimally invasive procedures enabled by interventional systems like Azurion are a key part of the diagnosis and treatment pathway for stroke, where every minute counts in conserving the patient’s quality-of-life.
  • Interventional systems are also used to precisely plan and carry out complex neurovascular procedures such as the repair of brain aneurysms and birth defects.
  • By allowing neuro interventionists to treat more patients, more efficiently, with potentially better outcomes, the new Philips Azurion neuro biplane system enhances both the staff and patient experience and contributes to lower cost of care.

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

Retrieved on: 
Monday, February 26, 2024
Cardiovascular disease, Risk, Conference, NAMS, Patient

Michael Davidson, Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 2:10 p.m.

Key Points: 
  • Michael Davidson, Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 2:10 p.m.
  • Leerink Global Biopharma Conference in Miami, FL on Monday, March 11, 2024.
  • Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 4:00 p.m.
  • Live webcasts of both the Cowen and Leerink presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com .

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Sale, CD19, Lupus, RNA, EAP, LNP, Liver, Cardiovascular disease, CRISPR Therapeutics, CRSP, Therapy, Vertex Pharmaceuticals, Sickle cell disease, Autoimmunity, T1D, G&A, Bill, Partnership, Pharmacology, Guide, SCD, TDT, Pharmacokinetics, Clinical trial, ANGPTL3, United, Hypertriglyceridemia, Medicaid, Research, Human, CRISPR, Gene editing, CD70, Stem cell, ADC, Risk, Genetics, Patient, SLE, KSA, Moyamoya disease, Pharmaceutical industry

R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.

Key Points: 
  • R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses were $16.5 million for the fourth quarter of 2023, compared to $21.2 million for the fourth quarter of 2022.
  • Collaboration Expense: Collaboration expense, net, was $20.0 million for the fourth quarter of 2023, compared to $6.8 million for the fourth quarter of 2022.
  • Net Income (Loss): Net income was $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the fourth quarter of 2022.

Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K

Retrieved on: 
Wednesday, February 21, 2024
SAN, Sepsis, Lipopolysaccharide, Toxicity, Inflammation, FDA, Form 10-K, Cardiovascular disease, Dialysis, IDE, Kidney disease, Annual report, Death, Patient, ESRD, Investigational device exemption, Mortality, Infection, Cancer, Pharmaceutical industry

SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today the filing of its Form 10-K annual report with the United States Securities and Exchange Commission ("SEC") for the year-ended December 31, 2023.

Key Points: 
  • SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today the filing of its Form 10-K annual report with the United States Securities and Exchange Commission ("SEC") for the year-ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov or on the Company's website at www.sigyntherapeutics.com under the "investors" section.
  • On January 31, 2024, the Company completed a 1-for-40 reverse split of its common stock.
  • In 2023, net cash used in operating activities was approximately $1.4 million, as compared to approximately $1.8 million in 2022.

NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors

Retrieved on: 
Monday, February 19, 2024
DOI, PCSK9, Fibrinolysis, Inflammation, Obesity, Cardiovascular disease, Weight loss, NLRP3, Fibrinogen, Astrogliosis, Biomarker, Therapy, Lipid metabolism, Patient, Journal, Experiment, Disease, Phases of clinical research, Mouse, Pharmaceutical industry

The data are published in the Journal of Pharmacology and Experimental Therapeutics in a paper titled ‘Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796’1.

Key Points: 
  • The data are published in the Journal of Pharmacology and Experimental Therapeutics in a paper titled ‘Reversal of high fat diet-induced obesity, systemic inflammation and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796’1.
  • The NLRP3 inflammasome is a highly validated anti-inflammatory drug target, and these findings demonstrate that NLRP3 plays a key role in controlling obesity and obesity-associated inflammation through the modulation of hypothalamic gliosis.
  • Both NT-0796 and NT-0249, two structurally distinct NLRP3 inhibitors in clinical development by NodThera, have generated a wealth of preclinical and clinical data demonstrating brain-penetration and broad anti-inflammatory effects, with NT-0796 being the first NLRP3 inhibitor to show reduced neuroinflammation in the clinic.
  • Our ongoing Phase IIa study in obese individuals at cardiovascular risk will further validate these pre-clinical findings.”
    Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.

New Data Published by Omada Health Demonstrates the Impact of Coupling GLP-1s and Behavior Change Programming

Retrieved on: 
Friday, March 8, 2024
Diabetes, Health, Cardiology, Telemedicine, Virtual Medicine, Obesity, Cardiovascular disease, Weight loss, Hope, Health care, Hypertension, Prediabetes, Express Scripts, Partnership

The Omada program is designed to help bolster the weight loss of EncircleRx members using GLP-1 medications for weight management.

Key Points: 
  • The Omada program is designed to help bolster the weight loss of EncircleRx members using GLP-1 medications for weight management.
  • The retrospective analysis found that individuals in the Omada for Prevention program who were using GLP-1s for weight loss had statistically better results when highly engaged in the Omada behavior change program.
  • Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time.
  • Omada care teams implement clinically validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, weight health and musculoskeletal issues.

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Retrieved on: 
Tuesday, March 5, 2024
Data Management, Health, Technology, Health Technology, Software, Artificial Intelligence, Cardiology, Cardiovascular disease, Personalized medicine, American Heart Association, Artificial intelligence, MD, Moyamoya disease, Patent, CVD, Entrepreneurship, Splenic infarction, Sudden death, European, Integration, University, Biomarker, CHD, Death, Risk assessment, Patient, Clinical trial, IP, Genomics, Heart, Diagnosis, Medicine, Pharmaceutical industry

This is the second U.S. patent being issued in this patent family.

Key Points: 
  • This is the second U.S. patent being issued in this patent family.
  • Patents in this patent family have also been issued in the European Union, China, India, and Australia.
  • According to the American Heart Association , cardiovascular disease (CVD) claims 2,552 lives daily in the United States, translating to a death every 34 seconds.
  • Heart disease, which includes heart attacks, has been the leading cause of death in the United States for 100 years.

Foldax, Inc. Signs Manufacturing Agreement with Dolphin Life Science India LLP to Expedite Upcoming Commercial Availability

Retrieved on: 
Tuesday, February 27, 2024
Research, Medical Devices, Engineering, Chemicals, Plastics, Health Technology, Cardiology, Manufacturing, Biotechnology, Health, Science, Anticoagulant, Cardiovascular disease, CDSCO, Sale, RHD, Calcification, Mitral valve, Patient, Anatomy, LLP, Failure, DCGI, TRIA, Medical device

Foldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing agreement with Dolphin Life Science India LLP to enable in-country manufacturing of the TRIA™ polymer mitral surgical heart valve outside of the U.S. for the first time.

Key Points: 
  • Foldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing agreement with Dolphin Life Science India LLP to enable in-country manufacturing of the TRIA™ polymer mitral surgical heart valve outside of the U.S. for the first time.
  • The TRIA mitral valve is designed specifically to accommodate the anatomy and pressures of the mitral position.
  • Dolphin Life Science India LLP is an expert in manufacturing medical devices.
  • The company is registered with India’s regulatory bodies, the Drugs Controller General of India (DCGI), and the Central Drugs Standard Control Organization (CDSCO).

Diabetes Research Study Evaluating a New Approach To Helping Patients Now Offered in Warwick

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Diabetes, Health, Women, Seniors, Men, Research, Family, Consumer, Science, Clinical Trials, Multimedia, Blood, Liver disease, Obesity, Cardiovascular disease, Stroke, Splenic infarction, DMR, Risk, Type 2 diabetes, BMI, Patient, Insulin, Medicine, Insulin resistance, Kidney disease, Duodenum, Medical device

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Key Points: 
  • A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.
  • (Photo: Business Wire)
    The combination of diabetes and obesity significantly increases one’s risk of heart attacks, stroke, liver disease, kidney disease, and other serious health problems.
  • Care Access is a global clinical research company helping to accelerate the future of medicine.
  • With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

Retrieved on: 
Wednesday, February 21, 2024
FDA, Health, Diabetes, Surgery, Health Insurance, Pharmaceutical, Therapy, CE, American Diabetes Association, NAFLD, Endocrinology, T2D, Research, Medicine, Person, CMS, Non-alcoholic fatty liver disease, Liver disease, NDRA, Prediabetes, Obesity, Cardiovascular disease, Food, ALT, De novo, Global health, Weill Cornell Medicine, Risk, Hepatology, Cirrhosis, European, Prevalence, Ultrasound, World Health Organization, Medicare, Type 2 diabetes, Metabolic syndrome, Patient, Fibrosis, Primary care, Fatty liver disease, NASH, Diagnosis, Knowledge Organization (journal), WHO, International Classification of Diseases, Dietary supplement

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.

Key Points: 
  • The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.
  • These codes are issued by the World Health Organization (WHO) and are used to show payers why a particular service was medically necessary.
  • The inclusion of NAFLD under the ICD-10 K76.0 code facilitates standardized billing for its diagnosis.
  • "This positive development is testament to the growing awareness of liver health and the intensifying need for effective diagnostic solutions.